286 related articles for article (PubMed ID: 32742264)
1. Targeting the Microenvironment in MDS: The Final Frontier.
Teodorescu P; Pasca S; Dima D; Tomuleasa C; Ghiaur G
Front Pharmacol; 2020; 11():1044. PubMed ID: 32742264
[TBL] [Abstract][Full Text] [Related]
2. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
3. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
4. What is the role of the microenvironment in MDS?
Calvi LM; Li AJ; Becker MW
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976
[TBL] [Abstract][Full Text] [Related]
5. Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells.
Wobus M; Mies A; Asokan N; Oelschlägel U; Möbus K; Winter S; Cross M; Weidner H; Rauner M; Hofbauer LC; Bornhäuser M; Platzbecker U
Leukemia; 2021 Oct; 35(10):2936-2947. PubMed ID: 34002031
[TBL] [Abstract][Full Text] [Related]
6. Improving Treatment for Myelodysplastic Syndromes Patients.
Montoro J; Yerlikaya A; Ali A; Raza A
Curr Treat Options Oncol; 2018 Oct; 19(12):66. PubMed ID: 30362079
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
8. Targeting inflammation in lower-risk MDS.
Gonzalez-Lugo JD; Verma A
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):382-387. PubMed ID: 36485128
[TBL] [Abstract][Full Text] [Related]
9. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
[TBL] [Abstract][Full Text] [Related]
10. Current and emerging strategies for management of myelodysplastic syndromes.
Saygin C; Carraway HE
Blood Rev; 2021 Jul; 48():100791. PubMed ID: 33423844
[TBL] [Abstract][Full Text] [Related]
11. Special Education: Aplastic Anemia.
Teramura M; Mizoguchi H
Oncologist; 1996; 1(3):187-189. PubMed ID: 10387986
[TBL] [Abstract][Full Text] [Related]
12. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
13. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
14. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.
Lindberg EH
Curr Drug Targets; 2005 Sep; 6(6):713-25. PubMed ID: 16178803
[TBL] [Abstract][Full Text] [Related]
15. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
Tauro S; Hepburn MD; Bowen DT; Pippard MJ
Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes.
Bains AK; Behrens Wu L; Rivière J; Rother S; Magno V; Friedrichs J; Werner C; Bornhäuser M; Götze KS; Cross M; Platzbecker U; Wobus M
Front Oncol; 2022; 12():961473. PubMed ID: 36158640
[TBL] [Abstract][Full Text] [Related]
17. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
18. [Research advance of hematopoietic microenvironment for myelodysplastic syndromes].
Fei CM; Chang CK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1246-50. PubMed ID: 23114158
[TBL] [Abstract][Full Text] [Related]
19. Mouse models of myelodysplastic syndromes.
Wegrzyn J; Lam JC; Karsan A
Leuk Res; 2011 Jul; 35(7):853-62. PubMed ID: 21466894
[TBL] [Abstract][Full Text] [Related]
20. Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes.
Kouroukli O; Symeonidis A; Foukas P; Maragkou MK; Kourea EP
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
